On 15th October 2024, Lily Lin, CEO of Excellence First Enterprise Consultancy, accompanied by Iris Li and Yang Qing from the Lingang Cambridge Network (LCN), visited Gluetacs Therapeutics, a pioneering biotech company and LCN member. Dr. Yang, the founder of Gluetacs, along with his colleagues, warmly welcomed Lily and provided updates on their recent North American business expansion.
Since Lily’s last face-to-face meeting in April this year with Dr Yang and his colleagues, the EFEC team has gained a deep understanding of Gluetacs’ vision and greatly admires Dr. Yang’s ambition to join the global life science ecosystem. Gluetacs aims to contribute to world health through cutting-edge technology and innovation. During the visit, Lily and Dr. Yang discussed in detail the key stages of this exciting initiative and envisioned how a team of excellent UK life sciences experts, with various specialised focuses, could support Gluetacs’ global success.
Background on Gluetacs Therapeutics
Gluetacs Therapeutics, founded in February 2020 and is based in the Lin-Gang Special Area of China (Shanghai) Pilot Free Trade Zone, specialises in targeted protein degradation. The company focuses on both molecular glue (GLUE) and bifunctional degrader (GLUETAC) technologies.
Key Achievements:
- Development of the proprietary GlueTacs® platform for drug discovery
- Filing of approximately 100 patents
- Advancement of two drug candidates to Phase I clinical trials
- Establishment of a comprehensive R&D system with AI-aided drug design
- Recent expansion into the North American market
Gluetacs is now seeking to expand its operations into the UK market to leverage the region’s robust biotech ecosystem
EFEC’s Expertise in Supporting Gluetacs’s UK Market Entry
EFEC plays a crucial role in bridging innovation and talent development between the UK and China. Our facilitation support for Gluetacs’ entry into the UK market includes:
- Navigating the complex UK regulatory landscape
- Assisting with operational setup and talent acquisition
- Facilitating partnerships with UK research institutions
- Bridging cultural gaps to foster genuine collaboration
- Guiding access to UK funding and investment opportunities
EFEC’s team and its strategic partners in the UK in these areas ensure that Gluetacs can establish a strong presence in the UK while navigating potential regulatory and geopolitical challenges.
